Top Page
BioHarvest Sciences
(NASDAQ:BHST)
BioHarvest Sciences (BHST) vs. SPDR S&P 500 ETF (SPY)
BioHarvest Sciences Business Overview & Revenue Model
BioHarvest Sciences Earnings Call Summary
BioHarvest Sciences Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.17M | 25.19M | 12.67M | 5.50M | 2.10M | 396.00K |
| Gross Profit | 17.50M | 13.94M | 5.63M | 1.22M | 670.00K | 138.00K |
| EBITDA | -5.82M | -9.72M | -9.76M | -9.13M | -8.51M | -5.77M |
| Net Income | -12.06M | -12.91M | -12.56M | -11.24M | -9.83M | -6.58M |
Balance Sheet | ||||||
| Total Assets | 27.80M | 25.00M | 15.00M | 9.39M | 10.21M | 5.30M |
| Cash, Cash Equivalents and Short-Term Investments | 3.73M | 2.39M | 5.36M | 1.74M | 4.12M | 1.78M |
| Total Debt | 21.09M | 13.82M | 22.34M | 10.56M | 2.66M | 2.71M |
| Total Liabilities | 32.02M | 23.67M | 29.86M | 15.32M | 7.35M | 7.60M |
| Stockholders Equity | -4.22M | 1.33M | -14.85M | -5.93M | 2.85M | -2.29M |
Cash Flow | ||||||
| Free Cash Flow | -9.21M | -9.52M | -10.00M | -10.50M | -8.43M | -4.05M |
| Operating Cash Flow | -7.03M | -6.68M | -8.52M | -9.24M | -6.79M | -3.88M |
| Investing Cash Flow | -2.14M | -3.03M | -1.47M | -1.26M | -1.64M | -173.00K |
| Financing Cash Flow | 7.80M | 6.78M | 13.56M | 8.14M | 10.77M | 4.93M |
BioHarvest Sciences Technical Analysis
BioHarvest Sciences Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $157.14M | 11.57 | 11.29% | 2.79% | -9.70% | -30.98% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
54 Neutral | $131.32M | ― | -28.29% | ― | 135.15% | 10.32% | |
50 Neutral | $152.71M | ― | -973.22% | ― | 57.83% | 40.94% | |
46 Neutral | $152.33M | ― | -298.41% | ― | 565.52% | 79.44% | |
40 Neutral | $142.75M | ― | 260.68% | ― | -36.29% | 36.16% | |
36 Underperform | $119.61M | ― | -287.92% | ― | ― | 97.61% |
BioHarvest Sciences Corporate Events
On September 10, 2025, BioHarvest Sciences announced a significant breakthrough in its Botanical Synthesis technology by successfully producing plant-based exosomes at scale in its bioreactors. This advancement not only enhances the company’s proprietary platform but also opens new revenue streams in the cosmetics, health, and pharmaceutical industries. The plant-based exosomes, enriched with viniferin, offer superior absorption and bioavailability, making them highly desirable for therapeutic and cosmetic applications. This development positions BioHarvest as a key player in the growing exosome market, which is expected to expand significantly by 2030.
On September 8, 2025, BioHarvest Sciences Inc. announced the filing and effectiveness of a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission. This registration allows the company to offer and sell up to USD $100 million of its securities, including common shares, warrants, and units, subject to market conditions and the company’s capital needs. This strategic move positions BioHarvest to potentially enhance its financial flexibility and market presence, although it does not obligate the company to sell any specific amount of securities.
On September 8, 2025, BioHarvest Sciences Inc. announced the effectiveness of its shelf registration statement on Form F-3 with the SEC, allowing the company to offer and sell up to USD $100 million of its securities, including common shares, warrants, and units. This strategic move provides BioHarvest with flexibility to raise capital as needed, subject to market conditions and SEC regulations, potentially strengthening its financial position and supporting its growth initiatives.
On August 13, 2025, BioHarvest Sciences announced that its board of directors has adopted an amended insider trading policy. The new policy adjusts the trading window to open after the close of trading on the second full trading day following the public release of quarterly or year-end results and closes fifteen days before the due date of these results. This change aims to provide a more reasonable trading period, potentially impacting how stakeholders engage with the company’s stock.
On August 13, 2025, BioHarvest Sciences Inc. announced the adoption of an amended insider trading policy by its board of directors. The new policy adjusts the trading window to open after the close of trading on the second full trading day following the public release of quarterly or year-end results and to close fifteen days before the due date of these results. This change is expected to provide a more reasonable trading period, potentially impacting the company’s operations by aligning trading activities with financial disclosures.
BioHarvest Sciences announced that it will release its second quarter 2025 financial results on August 11, 2025, before the market opens. The company will host an investor conference call and webcast on the same day to discuss the results and provide a corporate update, which may impact its market positioning and stakeholder engagement.
BioHarvest Sciences Inc. held its annual general and special meeting of shareholders on June 26, 2025, where all proposed motions were approved, including the election of directors, appointment of auditors, and the confirmation of the company’s Equity Incentive Compensation Plan. A significant amendment was made to the company’s articles to create a staggered board, enhancing board continuity by electing approximately one-third of the board annually, with directors serving three-year terms. This move is expected to stabilize the company’s governance structure and potentially improve strategic decision-making.